Form 4: Neurocrine Biosciences CMO Awarded Significant Equity Compensation

Neurocrine Biosciences' Chief Medical Officer, Sanjay Chandru Keswani, has been granted 12,846 Restricted Stock Units and 70,101 stock options as part of his compensation package.

Summary

• Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc. (NBIX), reported the acquisition of new equity securities.
• On June 2, 2025, Mr. Keswani was granted 12,846 Restricted Stock Units (RSUs).
• These RSUs will vest annually at 25% of the units on June 2, 2026, June 2, 2027, June 2, 2028, and June 2, 2029.
• Additionally, on June 2, 2025, Mr. Keswani was granted 70,101 stock options with an exercise price of $124.56.
• The stock options will vest 1/4th of the shares on June 2, 2026, and an additional 1/48th of the shares each month thereafter.
• The stock options have an expiration date of June 2, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine executive compensation grant, which is a positive for aligning management incentives with shareholder interests, but it does not contain information that would significantly alter the company's operational or financial outlook.

Positives

• The grant of equity compensation to a key executive like the Chief Medical Officer aligns his long-term interests with those of the shareholders.
• Equity awards are a standard component of executive compensation, incentivizing performance and retention.

Future Outlook

The document details future vesting schedules for equity awards, indicating a long-term incentive structure for the Chief Medical Officer. It does not provide forward-looking statements regarding company financial performance or strategic direction.

Industry Context

The granting of Restricted Stock Units and stock options to key executives is a common practice in the biotechnology and pharmaceutical industries. This form of compensation is widely used to attract, retain, and motivate top talent, aligning their financial incentives with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of equity grants, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotech and pharmaceutical sectors.
• While specific comparable companies or projects are not detailed in this filing, the general approach to executive equity compensation aligns with industry benchmarks for incentivizing senior leadership in growth-oriented life sciences companies.

Related Party Transactions

• The reported transactions are equity compensation grants from Neurocrine Biosciences Inc. to its Chief Medical Officer, Sanjay Chandru Keswani, which are considered related-party transactions in the context of executive remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's financial interests with shareholder value creation, potentially leading to more focused long-term performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs, though this specific filing is limited to one executive.

Next Steps

• Vesting of Restricted Stock Units annually from June 2, 2026, through June 2, 2029.
• Vesting of Stock Options beginning June 2, 2026, with monthly vesting thereafter until fully vested or expired.

Key Dates

Recommendation

Keywords

Neurocrine Biosciences, NBIX, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Sanjay Chandru Keswani, Chief Medical Officer, Insider Transaction